AHMED ELKHANANY to Disease Progression
This is a "connection" page, showing publications AHMED ELKHANANY has written about Disease Progression.
Connection Strength
0.034
-
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2. Ann Oncol. 2023 12; 34(12):1131-1140.
Score: 0.034